<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704181</url>
  </required_header>
  <id_info>
    <org_study_id>4436/16/102</org_study_id>
    <nct_id>NCT03704181</nct_id>
  </id_info>
  <brief_title>Colchicine for Patients With Chagas´ Disease( B1 Stage)</brief_title>
  <acronym>COACH</acronym>
  <official_title>Effect of Colchicine on Inflammation and Myocardial Fibrosis Assessed by Magnetic Resonance Imaging in Patients With Chagas' Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the addition of colchicine in the treatment of patients with
      Chagas´disease.

      Forty patients will receive colchicine while twenty patients will receive placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chagas disease is considered one of the main cause of dilated cardiomyopathy in Latin
      America. The histopathological characteristics of Chagas' disease are the presence of
      myocarditis, destruction of heart fibers, and severe myocardial fibrosis. Colchicine had a
      protective effect on myocardium, indicated by decreased interstitial myocardial fibrosis and
      attenuated myocardial inflammation. It is an inflammatory cause of cardiomyopathy and
      myocardial fibrosis is the hallmark of this disease. Colchicine is a drug used in
      inflammatory diseases, and could also act on myocardial remodeling interfering in the
      synthesis of collagen
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">January 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of colchicine on myocardial inflammation assessed by magnetic resonance imaging</measure>
    <time_frame>1 year</time_frame>
    <description>myocardial edema quantified in grams or percent of LV mass, myocardial hyperaemia quantified in grams or percent of LV mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of colchicine on myocardial fibrosis assessed by magnetic resonance imaging</measure>
    <time_frame>1 year</time_frame>
    <description>myocardial fibrosis quantified in grams or percent of LV mass</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of colchicine on inflammatory markers such as interleukin-1, interleukin-6, interleukin-8, interleukin-10</measure>
    <time_frame>1 year</time_frame>
    <description>interleukin-1, interleukin-6, interleukin-8, interleukin-10, ELISA (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of colchicine on inflammatory marker such as TNF-α</measure>
    <time_frame>1 year</time_frame>
    <description>TNF-α ELISA (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of colchicine on inflammatory marker such as interferon-gama</measure>
    <time_frame>1 year</time_frame>
    <description>Interferon -gama ELISA (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of colchicine on T Cruzi polymerase chain reaction</measure>
    <time_frame>1 year</time_frame>
    <description>7500 PCR-Real time System (Life Technologies)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chagas Disease</condition>
  <condition>Colchicine Resistance</condition>
  <arm_group>
    <arm_group_label>colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colchicine 0,5 milligram tablet by mouth every 12 hours, for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo tablet by mouth every 12 hours, for 1 year
pill manufactured to mimic coclchicine 0,5 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 0.5 MG twice day for one year</intervention_name>
    <description>placebo twice day for one year</description>
    <arm_group_label>colchicine</arm_group_label>
    <other_name>placebo oral tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo twice day for one year</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and serological diagnosis of Chagas´disease ( Stage B1)

          -  Must be able to swallow tablets

        Exclusion Criteria:

          -  myocardial infarction or coronary artery disease,

          -  diabetes mellitus,

          -  valvular disease,

          -  creatinine clearance &lt;30 ml / kg / min

          -  contraindication to perform cardiac magnetic resonance imaging

          -  use of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and
             aldosterone blockers

          -  previous use of benzonidazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Fernandes, Md, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute, University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Fernandes, MD, PHD</last_name>
    <phone>+55 11 2661 5057</phone>
    <email>fabio.fernandes@incor.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula Buck, PHD</last_name>
    <phone>+55 11 2661 5346</phone>
    <email>carpaula@incor.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fabio Fernandes</name>
      <address>
        <city>São Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Fernandes, MD</last_name>
      <phone>+55 11 997681946</phone>
      <email>fabio.fernandes@incor.usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrosis</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

